- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04235101
Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors
A Two-part Phase I Study With the Antibody-drug Conjugate SYD985 in Combination With Niraparib to Evaluate Safety, Pharmacokinetics and Efficacy in Patients With HER2-expressing Locally Advanced or Metastatic Solid Tumors.
Study Overview
Detailed Description
This is an open-label, single-arm study in which patients with HER2-expressing locally advanced or metastatic solid tumours will be treated with both an anti-body drug conjugate SYD985 and a Poly (ADP-ribose) Polymerase (PARP) inhibitor niraparib. SYD985 is an antibody-drug conjugate and consists of two parts. The antibody part binds to a protein that exists on different types of cancer cells (HER2 protein). When SYD985 binds to this protein, it will be taken up by the cancer cell. The second part of the drug, a toxin, will be cleaved in the cell and subsequently kills the cancer cell. Niraparib blocks the action of enzymes PARP-1 and PARP-2, which help to repair damaged DNA in cells when the cells divide to make new cells. By blocking PARP enzymes, the damaged DNA in cancer cells cannot be repaired, and, as a result, the cancer cells die.
Part 1 includes patients with locally advanced or metastatic HER2-expressing solid tumours of any origin that showed progression on standard therapy or for whom no standard therapy exists. Patients will receive SYD985 infusions every three weeks in combination with niraparib until progression of the cancer or unacceptable toxicity develops. In this first part of the study, different doses of niraparib will be given for either 1, 2 or 3 weeks.
Part 2 includes patients with advanced or metastatic breast, ovarian or endometrial cancer that showed progression on standard therapy or for whom no standard therapy exists. Patients will receive SYD985 infusions every three weeks in combination with niraparib until progression of the cancer or unacceptable toxicity develops.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Antwerp, Belgium, 2650
- University Hospital Antwerp, BE
-
Brussel, Belgium, 1000
- Institut Jules Bordet
-
-
-
-
-
Nijmegen, Netherlands, 6500 HB
- Radboud University Medical Center/ NL
-
-
-
-
-
London, United Kingdom, SM2 5PT
- The Royal Marsden NHS Foundation Trust
-
Manchester, United Kingdom, M20 4BX
- The Christie NHS Foundation Trust/ UK
-
Newcastle, United Kingdom, NE7 7DN
- The Newcastle upon Tyne Hospitals NHS Foundation Trust/UK
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female, age ≥ 18 years at the time of signing first informed consent;
Patient with a histologically-confirmed, locally advanced or metastatic tumour who has progressed on standard therapy or for whom no standard therapy exists, with the following restriction:
- Part 1: solid tumours of any origin;
- Part 2: breast cancer, ovarian cancer or endometrial carcinoma/carcinosarcoma;
- HER2 tumor status at least 1+ as assessed by immunohistochemistry (IHC) as determined by the local laboratory;
- Presence of a tumor lesion accessible for biopsy and patient should be willing to undergo a fresh biopsy for central HER2 testing and genetic testing, unless adequate (biopsy) tumour material is available obtained < 6 months prior to signing the main informed consent;
- At least one measurable cancer lesion as defined by the Response Evaluation Criteria for Solid Tumours (RECIST version 1.1);
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1;
- Adequate organ function.
Exclusion Criteria:
Having been treated with:
- DUBA-containing ADCs at any time;
- Anthracycline treatment within 8 weeks prior to start of study treatment;
- Other anticancer therapy including chemotherapy, immunotherapy, or investigational agents within 4 weeks prior to start of study treatment or 5 times the half-life of the therapy, whichever is shorter;
- Radiotherapy within 4 weeks prior to start of study treatment or within 1 week for palliative care (as long as the lungs were not exposed);
- Hormone therapy within 1 week prior to start of study treatment. The patient must have sufficiently recovered from any treatment-related toxicities to NCI CTCAE Grade ≤ 1 (except for toxicities not considered a safety risk for the patient at the investigator's discretion);
- History or presence of keratitis;
- Left ventricular ejection fraction (LVEF) < 50% as assessed by either echocardiography or multigated acquisition (MUGA) scan at screening, or a history of clinically significant decrease in LVEF during previous trastuzumab containing treatment leading to permanent discontinuation of treatment;
- History (within 6 months prior to start of study treatment) or presence of clinically significant cardiovascular disease such as unstable angina, congestive heart failure, myocardial infarction, uncontrolled hypertension, or cardiac arrhythmia requiring medication;
- History or presence of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan;
- Severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary, or metabolic disease) at screening;
- Symptomatic brain metastases, brain metastasis requiring steroids to manage symptoms or treatment for brain metastases within 8 weeks prior to start of study treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SYD985 + Niraparib
SYD985, Intravenous, every 3 weeks (Q3W) Niraparib taken orally and either 100 mg, 200 mg or 300 mg once daily for either 1, 2 or 3 weeks.
|
SYD985 powder for concentrate for solution for infusion Niraparib 100 mg per hard capsule
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of dose-limiting toxicities
Time Frame: 21 days
|
First cycle
|
21 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with adverse events
Time Frame: up to 2 years
|
up to 2 years
|
Change from baseline in hematology and blood chemistry parameters
Time Frame: Baseline and every cycle up to 2 years
|
Baseline and every cycle up to 2 years
|
Number of patients with antibodies against SYD985
Time Frame: Baseline and every cycle up to 2 years
|
Baseline and every cycle up to 2 years
|
Area under the plasma concentration versus time curve (AUC) of SYD985 and niraparib
Time Frame: Baseline, Days 1,8,15 of Cycle 1, Days 1,8,15 of Cycle 2, Day 1 of subsequent cycles up to 6 months
|
Baseline, Days 1,8,15 of Cycle 1, Days 1,8,15 of Cycle 2, Day 1 of subsequent cycles up to 6 months
|
Peak plasma concentration of SYD985 and niraparib
Time Frame: Baseline, Days 1,8,15 of Cycle 1, Days 1,8,15 of Cycle 2, Day 1 of subsequent cycles up to 6 months
|
Baseline, Days 1,8,15 of Cycle 1, Days 1,8,15 of Cycle 2, Day 1 of subsequent cycles up to 6 months
|
Objective response rate
Time Frame: Baseline and every two cycles for up to 6 months, subsequent every 4 cycles up to 2 years
|
Baseline and every two cycles for up to 6 months, subsequent every 4 cycles up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Norbert Koper, Byondis B.V., The Netherlands
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SYD985.004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on SYD985 + Niraparib
-
Byondis B.V.CompletedMetastatic Breast CancerFrance, Belgium, Spain
-
Tesaro, Inc.Completed
-
Tesaro, Inc.Active, not recruiting
-
Virginia Commonwealth UniversityGlaxoSmithKline; Puma Biotechnology, Inc.RecruitingOvarian Cancer | Advanced Solid TumorUnited States
-
Byondis B.V.CompletedSolid TumorsNetherlands, Belgium, United Kingdom, Spain
-
Fudan UniversityRecruitingTreatment EfficacyChina
-
QuantumLeap Healthcare CollaborativeByondis B.V.WithdrawnOvarian Cancer | Metastatic Cancer | Metastatic Breast Cancer | Bladder Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Gastroesophageal Adenocarcinoma | Ovarian Carcinoma | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoid Tumor | HER2-positive Metastatic Breast... and other conditionsUnited States
-
Chongqing University Cancer HospitalRecruiting
-
Byondis B.V.CompletedEndometrial CancerKorea, Republic of, Singapore, Russian Federation, Ukraine, United States, Poland, Serbia
-
German Breast GroupGlaxoSmithKline; Stemline Therapeutics, Inc.Not yet recruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast CancerGermany